Indications:
Treatment of edema after trauma, surgery, burns.
Administration – dosage:
Administration: AGICHYMO can be taken orally or sublingually.
Dosage:
1 tablet/time x 3 – 4 times per day, no chewing. 2 – 3 tablets/day may be given sublingually.
Some special attention on the handling of the medicine before and after use:
There are no special requirements for handling this medicine after use.
Contraindications:
Hypersensitivity to chymotrypsin or any of the excipients of the medicine.
Warnings and precautions for use:
Due to possibility of vitreous humour loss, chymotrypsin is not recommended in cataract surgery in patients under 20 years old. Do not use chymotrypsin for patients who have vitreous humour hypertension and open wounds or for congenital cataract patients.
This medicine contains lactose: Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Pregnancy and lactation:
Pregnancy:
There are no data on the use of chymotrypsin in pregnant women, this drug should only be used if the benefits outweigh the risks. So to be safe, avoid using this drug for pregnant women.
Women of childbearing age or who are using birth control methods should consult their doctor carefully before taking this medicine.
Lactation:
There are no data on the use of chymotrypsin in lactation women, the drug should only be used if the benefits outweigh the risks. To be safe, avoid using this drug for lactating women.
Effects on ability to drive and use machines:
Taking this medicine orally or sublingually has no effects on ability to drive and use machines.
Interactions, incompatibilities of medicine:
Interaction with other medical products and other forms of interaction:
There are no reported documents.
Incompatibilities:
Because there are no studies of drug incompatibility, do not mix this drug with other drugs.
Undesirable effects:
Currently, ADR has only been recorded in cases of adjuvant use in cataract surgery, ophthalmology may experience corneal edema, mild uveitis, and parenteral reactions.
Inform your physicians immediately about undesirable effects encountered when using the drug.
Overdose and management:
In mice, rats, rabbits and dogs; LD50 = 24,000 – 85,000 units/kg. Causes bleeding in many organs. In humans, there have been no reports. Anaphylactic shock may occur.
Pharmacodynamics:
Pharmacotherapeutic group: Non-steroidal anti-inflammatory drugs (protein hydrolytic enzymes).
ATC code: B06AA04.
Chymotrypsin is a proteolytic enzyme, prepared by activating chymotrypsinogen extracted from bovine pancreas. Chymotrypsin specifically cuts the chain links of aromatic amino acids (phenylamine, tyrosine, tryptophan, methionine, norleucine and norvaline), so it breaks down vitreous zonules without causing severe damage to other structures of the eyes.
Chymotrypsin has also been used to treat edema caused by inflammation, after trauma, and after surgery. This drug has little evidence of an anti-inflammatory effect in other inflammatory diseases (respiritis, sinusitis, etc.).
Pharmacokinetics:
Chymotrypsin crosses the intestinal barrier and enters the bloodstream via the lymphatic route. In the blood, chymotrypsin gradually migrates to the sites of inflammation and gradually decreases in blood concentration.
